TransCode Therapeutics has advanced TTX-MC138 into Phase 2a, so why is it exploring a sale or strategic partnership?
TransCode appoints Tungsten Advisors to explore TTX-MC138 licensing and sale options as its ctDNA-positive colorectal cancer trial advances.